{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:09:49Z","timestamp":1792123789226,"version":"4.4.0"},"reference-count":23,"publisher":"Informa UK Limited","issue":"16","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/14796694.2025.2511562","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:37:17Z","timestamp":1749199037000},"page":"2067-2075","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis"],"prefix":"10.1080","volume":"21","author":[{"given":"Lucia","family":"Masarova","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Wake Health","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Dobi","sequence":"additional","affiliation":[{"name":"Evidera","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ellis","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwaipayan","family":"Patnaik","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Baar, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Liu","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[{"name":"Evidera","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"e_1_3_8_3_1","unstructured":"Bristol Myers Squibb. Inrebic [Prescribing information]. 2022. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_inrebic.pdf"},{"key":"e_1_3_8_4_1","unstructured":"CTI Biopharma Corp. Vonjo (pacritinib). Prescribing information. 2022."},{"key":"e_1_3_8_5_1","unstructured":"Incyte Corporation. Jakafi (ruxolitinib). Prescribing information. 2021. Available from: https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2294324"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17727"},{"key":"e_1_3_8_10_1","unstructured":"GSK. Ojjaara [Prescribing information]. 2023. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009311"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01439-2"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010151"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.015"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.016"},{"key":"e_1_3_8_23_1","unstructured":"Bristol Myers Squibb. Inrebic (fedratinib). Summary of product characteristics. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inrebic-epar-product-information_en.pdf"},{"key":"e_1_3_8_24_1","volume-title":"Transfusion independence response (TI-R) as a potential surrogate for overall survival (OS) in Janus kinase inhibitor (JAKi)-experienced patients with myelofibrosis from MOMENTUM trial","author":"Verstovsek S","year":"2022","unstructured":"Verstovsek S, Oh ST, Kiladjian JJ, et al., editors. Transfusion independence response (TI-R) as a potential surrogate for overall survival (OS) in Janus kinase inhibitor (JAKi)-experienced patients with myelofibrosis from MOMENTUM trial. New Orleans (LA): ASH; 2022."},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2511562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:21:25Z","timestamp":1763043685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2511562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/14796694.2025.2511562"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2511562","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}